NCT02452723 is a Phase 1 clinical trial of ISC-hpNSC in Parkinson Disease, sponsored by Cyto Therapeutics Pty Limited.

Who is sponsoring NCT02452723?

NCT02452723 is sponsored by Cyto Therapeutics Pty Limited.

What drugs are being tested in NCT02452723?

Interventions in NCT02452723: ISC-hpNSC.

What condition does NCT02452723 study?

NCT02452723 studies Parkinson Disease.

Is NCT02452723 still recruiting?

NCT02452723 is currently completed. Last updated 16 January 2026.

Last reviewed 2026-01-16 · How we verify

NCT02452723

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Single Arm, Open-Label Phase 1 Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease

Completed Phase 1 Last updated 16 January 2026

What this trial tests

Phase 1 trial testing ISC-hpNSC in Parkinson Disease in 12 participants. Completed in 1 September 2025.

Timeline

1 July 2016

Primary endpoint
18 June 2025

1 September 2025

Quick facts

Lead sponsor	Cyto Therapeutics Pty Limited
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 July 2016
Primary completion	18 June 2025
Estimated completion	1 September 2025
Sites	1 location across Australia

Drugs / interventions tested

ISC-hpNSC — full drug profile →

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Cyto Therapeutics Pty Limited — full company profile →

Who can join

Adults 30 to 70, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, related TEAEs, severe TEAEs
Time frame: 12 month

Sponsor's own description

This study will evaluate the safety of an investigational cell transplantation therapy, ISC-hpNSC, in patients with Parkinson's disease. All patients will receive the therapy, which consists of human neural stem cells. Three dose levels will be examined in the study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions.
Dong-Chen X, Yong C, Yang X, Chen-Yu S, et al · · 2023 · cited 258× · PMID 36810524 · DOI 10.1038/s41392-023-01353-3
Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease.
Doi D, Magotani H, Kikuchi T, Ikeda M, et al · · 2020 · cited 257× · PMID 32632153 · DOI 10.1038/s41467-020-17165-w
Pluripotent Stem Cells: Current Understanding and Future Directions.
Romito A, Cobellis G. · · 2016 · cited 130× · PMID 26798367 · DOI 10.1155/2016/9451492
iPS cell-based therapy for Parkinson's disease: A Kyoto trial.
Takahashi J. · · 2020 · cited 129× · PMID 33490319 · DOI 10.1016/j.reth.2020.06.002
Cell therapies in the clinic.
Wang LL, Janes ME, Kumbhojkar N, Kapate N, et al · · 2021 · cited 99× · PMID 34027097 · DOI 10.1002/btm2.10214
Therapeutic Plasticity of Neural Stem Cells.
Ottoboni L, von Wunster B, Martino G. · · 2020 · cited 69× · PMID 32265815 · DOI 10.3389/fneur.2020.00148
Emerging Therapeutic Strategies for Parkinson's Disease and Future Prospects: A 2021 Update.
Gouda NA, Elkamhawy A, Cho J. · · 2022 · cited 57× · PMID 35203580 · DOI 10.3390/biomedicines10020371
Stem Cell-Based Therapies for Parkinson Disease.
Liu Z, Cheung HH. · · 2020 · cited 55× · PMID 33137927 · DOI 10.3390/ijms21218060

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02452723 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cyto Therapeutics Pty Limited
Last refreshed: 16 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02452723.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing